Clinical trials: Squamous Cell Carcinoma of Anal Canal
Squamous Cell Carcinoma of Anal Canal
Nimotuzumab With Radiotherapy in the Treatment of Anal Canal Cancers
The objective of this study is to demonstrate the feasibility of using Nimotuzumab and radiation in the treatment of squamous cell carcinomas of the anal canal in order to achieve a 65% local control rate with a better toxicity…
- Trial name
- NCT01382745
- Testing
- Nimotuzumab, Intensity Modulated Radiation Therapy (IMRT)
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- Dr. Te Vuong
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell cancer.
- Conditions
- Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
- Trial name
- NCT03690921
- Testing
- Cisplatin, Fluorouracil, Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Breast Carcinoma
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma, Breast Carcinoma, Hepatocellular Carcinoma, Urothelial Carcinoma
- Trial name
- DUET-2 (NCT03517488)
- Testing
- XmAb20717
- Where
- 17 sites in United States
- Volunteers
- 150 people
- Sponsor
- Xencor, Inc.
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of Anal Canal
A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)
The purpose of this study is to assess the efficacy of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemotherapy.
- Trial name
- NCT03597295
- Testing
- Retifanlimab
- Where
- 46 sites in United States, Belgium and 7 more
- Volunteers
- 94 people
- Sponsor
- Incyte Corporation
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer.
- Conditions
- Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma
- Trial name
- NCT04166318
- Testing
- Biopsy, Biospecimen Collection, Capecitabine
- Where
- 659 sites in United States
- Volunteers
- 252 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Squamous Cell Carcinoma of the Anal Canal
Becotatug Vedotin Plus Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy-Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal
This is a single-arm, exploratory clinical study intended to enroll patients with EGFR-positive Locally Advanced Squamous Cell Carcinoma of the Anal Canal (T2-4N0-1M0).
- Trial name
- NCT07800000
- Testing
- Induction therapy, Concurrent chemoradiotherapy-immunotherapy, Maintenance therapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Wang Xin
Anal Cancer
Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00423293
- Testing
- fluorouracil, mitomycin C, Intensity-modulated radiation therapy
- Where
- 172 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Radiation Therapy Oncology Group
Ovarian Cancer, Bladder Cancer
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as…
- Conditions
- Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04580485
- Testing
- INCB106385, INCMGA00012
- Where
- 27 sites in United States, Belgium and 4 more
- Volunteers
- 54 people
- Sponsor
- Incyte Corporation
Anal Canal Carcinoma
Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma
Squamous cell carcinoma of the anal canal (SCCA) is a rare disease and mostly diagnosed at an early stage. After standard concurrent chemoradiation (CRT) with mitomycin (MMC) and 5-fluorouracil (5FU), the disease will recur in…
- Trial name
- Epitopes-HPV02 (NCT02402842)
- Testing
- Docetaxel, Cisplatin and 5-Fluorouracil
- Where
- 16 sites in France
- Volunteers
- 70 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and that has spread from where it first started…
- Conditions
- Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
- Trial name
- NCT02314169
- Testing
- Biospecimen Collection, Computed Tomography, Ipilimumab
- Where
- 56 sites in United States, Canada
- Volunteers
- 143 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma of Anal Canal
Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal
There is increasing evidence of a role of EGFR, treatment with EGFR-inhibitors in anal cancer and synergies of EGFR-inhibitors with radiotherapy.
- Trial name
- NCT01843452
- Testing
- RADIOTHERAPY, PANITUMUMAB, MITOMYCIN
- Where
- 4 sites in Switzerland
- Volunteers
- 8 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Squamous Cell Carcinoma of the Anal Canal
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.
- Trial name
- NCT04472429
- Testing
- carboplatin, paclitaxel, retifanlimab
- Where
- 84 sites in United States, Australia and 11 more
- Volunteers
- 308 people
- Sponsor
- Incyte Corporation
Anal Canal Cancer, Anal Squamous Cell Carcinoma
PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients
Locally Advanced Anal Canal Squamous Carcinoma Patients will be enrolled and given four cycles of neoadjuvant PD-1 antibody toripalimab combined with docetaxol and cisplatin, followed by radiotherapy and two cycles of concurrent…
- Conditions
- Anal Canal Cancer, Anal Squamous Cell Carcinoma, Anal Cancer, Anal Canal Cancer Stage I
- Trial name
- NCT05060471
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Sun Yat-sen University
Anal Canal Cancer
Immunomonitoring and Biomarker Research in Patients With Squamous Cell Anal Carcinoma
Even if squamous cell carcinoma of the anal canal (SCCA) is a rare disease, its incidence increases worldwide. SCCA is mostly induced by Human papillomavirus (HPV) infections and HPV-related oncoproteins (E6 and E7) are expressed…
- Trial name
- LAND (NCT03942900)
- Testing
- Additional biological samples
- Where
- 2 sites in France
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Cancer, Esophagus Squamous Cell Carcinoma
Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy
This is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of…
- Conditions
- Cancer, Esophagus Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Anal Canal Squamous Cell Carcinoma
- Trial name
- MASST (NCT03712566)
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- University Health Network, Toronto
Squamous Carcinoma, Head and Neck Cancer
Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer
The study's aim is to define imaging and molecular bio-markers for prediction of radiotherapy response of squamous cell carcinomas, in an early treatment phase.
- Conditions
- Squamous Carcinoma, Head and Neck Cancer, Anal Cancer, Lung Cancer
- Trial name
- MORRIS (NCT02379039)
- Where
- Sweden
- Volunteers
- 118 people
- Sponsor
- Umeå University
Anal Cancer, Rectal Cancer
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
This is a single arm Phase 2 study. Stage 1 and 2 of the study are monotherapy evaluations of ADXS11-001 in 31 and 24 participants, respectively with persistent/recurrent, loco-regional or metastatic squamous cell carcinoma…
- Trial name
- NCT02399813
- Testing
- Axalimogene filolisbac
- Where
- 10 sites in United States
- Volunteers
- 36 people
- Sponsor
- Advaxis, Inc.
Anal Cancer
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
RATIONALE: Drugs used in chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00324415
- Testing
- cetuximab, cisplatin, fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- AIDS Malignancy Consortium